Asia-Pacific Osteoporosis Therapeutics Market to 2024| Eli Lilly, Novartis, Pfizer, Amgen, Merck, Novo nordisk, Actavis, Roche

Albany, NY, 21st January : Recent research and the current scenario as well as future market potential of "Osteoporosis Therapeutics in Asia-Pacific Markets to 2024 - Growth Driven by ongoing Transition from Anti-resorptive Agents to Anabolic Therapies, Rising Prevalence, and Growing Awareness" globally.

Osteoporosis is a “silent epidemic” and as per the WHO declarations, it is a priority health issue. Osteoporosis is a disruption of bone architecture and decrease in bone mass, leading to a number of complications including increased chances of bone fractures and reduced bone strength. The most common sites of osteoporosis are the spine, hip and forearm, although it also affects other body parts.

Get PDF for more Professional and Technical insights @ https://www.researchmoz.us/enquiry.php?type=S&repid=1866893

The chronic nature of the disease, which requires ongoing treatment, relatively high annual cost of therapy (ACoT) of premium therapies, increasing prevalence and awareness about the disease among the patients over a period of time, and growing demand for mainly anabolic therapies, with only one anabolic therapy currently available in the market, have made osteoporosis treatment a highly lucrative market.

The osteoporosis therapeutic market has become very competitive due to the high number of new drug approvals, although the majority of them are incremental innovations of existing therapies. Competition is fierce, particularly among bisphosphonates and selective estrogen receptor modulators (SERMs), which are mostly used as first-line therapy and dominate the treatment market for osteoporosis patients.

Lack of effective and safe therapeutic options to treat osteoporosis was the major reason for development of currently marketed premium anabolic therapies. The competition among the premium therapies is expected to intensify during the forecast period due to expected launch of pipeline products. Additionally the expected launch of biosimilars will add fuel to the intense competition and make it tough for premium therapies to gain market share in the forecast period.

Patient compliance for osteoporosis therapies is a major unmet need, as the disease is asymptomatic until a fracture occurs and requires ongoing treatment. Drug delivery is crucial in the choice of medication.

Most medicines are administered orally, while others are administered intranasally or through injections. Medications with decreased dosing are often the preferred options. Therefore convenient and safe administration without significant compromise of therapy efficacy remains an unmet need.

View Complete TOC with tables & Figures @ https://www.researchmoz.us/osteoporosis-therapeutics-in-asiapacific-markets-to-2024-growth-driven-by-ongoing-transition-from-antiresorptive-agents-to-anabolic-therapies-rising-prevalence-and-growing-awareness-report.html/toc

Scope

The current Asia-Pacific osteoporosis market contains novel products, including a humanized anti-sclerostin mAb, a synthetic peptide analog of human PTHrP, and a recombinant peptide and analogue of PTH.
What are the competitive advantages of the novel drugs over current marketed drugs?
Bisphosphonates and SERMs dominate the osteoporosis market. However, unmet needs exist in terms of safety and efficacy.
Will the drugs under development fulfill the unmet needs of the osteoporosis market?
The pipeline contains a range of molecule types and molecular targets, including those that are well established in osteoporosis, and novel, first-in-class therapies. There are over 136 active pipeline molecules, and most of the late-stage investigational drug candidates feature improved dosing regimens and administration routes in comparison to currently marketed products and combination therapies.
Which classes of novel drugs are most prominent in the pipeline?
What is the potential for pipeline products to address unmet needs in the osteoporosis market?
Will the pipeline address unmet needs related to limited anabolic therapies for osteoporosis patients?
Analysis of clinical trials since 2006 identified that the failure rates of osteoporosis molecules were highest in Phase III, with the overall attrition rate for osteoporosis standing at 83%.
How do failure rates vary by stage of development, molecule type, and molecular target?
How do other factors, such as average trial duration and trial size, influence the costs and risks associated with product development?
Over the 2017-2024 forecast period, the Asia-Pacific osteoporosis therapeutics market is expected to increase in value at a compound annual growth rate of 5.9%.
Which markets make the most significant contribution to the current market size?
What are the epidemiology trends in these markets?
Will new market entrants lead to substantial changes in annual therapy costs?
How will immunotherapies such as Prolia contribute to growth?
How will different treatment usage patterns impact growth in the five assessed Asia-Pacific markets?
How will the annual cost of therapy and market size vary between the five Asia-Pacific markets?
What effect will the patent expirations of currently branded therapies have on market value?
A rising osteoporosis prevalence population and the uptake of newer therapies will lead to significant market growth over the forecast period, despite the launch of biosimilars.
Will the launch of biosimilars or emerging pipeline molecules threaten the commercial success of existing drugs?
Various drivers and barriers will influence the market over the forecast period.
What are the barriers that limit the uptake of premium-priced therapeutics in the assessed countries?
Which factors are most likely to drive the market in these countries?
Licensing deals are the most common form of strategic alliance in the osteoporosis therapeutics market, with deal values ranging from under $10m to over $200m.
How do deal frequency and value compare between target families and molecule types?
What were the terms and conditions of key licensing deals?

Reasons to buy

Understand the clinical context of osteoporosis by considering epidemiology, symptoms, etiology and pathophysiology, diagnosis, prognosis, treatment guidelines and options, and local and national registries.
Identify the therapeutic strategies, products, and companies that dominate the current marketed products landscape and recognize gaps and areas of unmet need.
Identify key pipeline trends in terms of molecule type, administration route, molecular target, and novelty.
Consider market opportunities and potential risks by examining trends in osteoporosis clinical trial size, duration, and failure rate by stage of development, molecule type, and molecular target.

Make An Enquiry @ https://www.researchmoz.us/enquiry.php?type=E&repid=1866893

Recognize the late-stage pipeline molecules that have demonstrated strong therapeutic potential in osteoporosis by examining clinical trial data and multi-scenario product forecast projections.
Compare treatment usage patterns, annual therapy costs, and market growth projections for India, China, Australia, Japan and South Korea.
Discover trends in licensing and co-development deals concerning osteoporosis products and identify the major strategic consolidations that have shaped the commercial landscape.

ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.

Mr. Nachiket Ghumare,
ResearchMoz,
90 State Street, Albany NY, United States,
Tel: +1-518-621-2074,
USA-Canada Toll Free: 866-997-4948,
Email: sales@researchmoz.us,
Follow me on : https://marketinfo247.wordpress.com/

This release was published on openPR.